Even before the second dose, BNT162b2 was highly efficacious, with a vaccine efficacy of 92.6%, a finding similar to the first-dose efficacy of 92.1% reported for the mRNA-1273 vaccine (Moderna).3
https://www.nejm.org/doi/full/10.1056/NEJMc2036242
The second dose is about increasing antibody...